title: Evaluating drug treatments for Parkinson's disease: how good are the trials?
authors.affiliation: Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2RR, UK. k.wheatley@bham.ac.uk
authors.forename: Keith
authors.initials: K
authors.lastname: Wheatley
authors.forename: Rebecca L
authors.initials: RL
authors.lastname: Stowe
authors.forename: Carl E
authors.initials: CE
authors.lastname: Clarke
authors.forename: Robert K
authors.initials: RK
authors.lastname: Hills
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Williams
authors.forename: Richard
authors.initials: R
authors.lastname: Gray
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D002394:Catechol O-Methyltransferase